Brand and Other Names:Neulasta
- Classes: Hematopoietic Growth Factors
Dosing & Uses
Dosage Forms & Strengths
Myelosuppressive Chemotherapy Adjunct
6mg SC once per chemotherapy cycle
Not for administration in the period 14 days before & 24 hours after admin of cytotoxic chemotherapy
Indicated to decrease incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy assoc with febrile neutropenia
Orphan designation for treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident
- Amgen, Inc.; One Amgen Center Drive M/S 17-2-B; Thousand Oaks, CA 91320-1799
Dosage Forms & Strengths
Prevention of Chemotherapy Induced Neutropenia
<45 kg: 100 mcg/kg per chemotherapy cycle; not to exceed 6 mg/dose; do not administer in the period 14 days before and 24-72 hr after administration of cytotoxic chemotherapy
≥45kg: 6 mg SC once per chemotherapy cycle; do not administer in the period 14 days before and 24 hr after administration of cytotoxic chemotherapy
Peripheral edema (12%)
Bone pain (31-57%)
Frequency Not Defined
Acute respiratory distress syndrome
Sickle cell crisis
Elevated lactate dehydrogenase
Elevated alkaline phosphatase
Gastrointestinal disorders: Splenic rupture
Blood and lymphatic system disorder: Sickle cell crisis
Hypersensitivity Reactions: Allergic reactions/hypersensitivity, including anaphylaxis, skin rash, and urticaria, generalized erythema and flushing, cutaneous vasculitis to skin, and subcutaneous tissue disorders
Respiratory, thoracic, and mediastinal disorder: ARDS
General disorders and administration site conditions: Injection site reactions
Skin and subcutaneous tissue disorders: Sweet’s syndrome, cutaneous vasculitis
Hypersensitivity to E. coli derived proteins or any component
Permanently discontinue therapy if serious allergic reaction occurs
Capillary leak syndrome may occur; may vary in frequency and severity; manage symptoms; delayed treatment may be life-threatening
Glomerulonephritis reported; if suspected, evaluate for cause; if causality likely, consider dose-reduction or interruption of therapy
Monitoring of complete blood count (CBC) during therapy recommended; higher counts reported
Acute respiratory distress syndrome (ARDS) reported; evaluate symptoms including fever, pulmonary infiltrates, or respiratory distress; discontinue if ARDS occurs
Not for use 14 days before or 24 hr after administering cytotoxic chemotherapy, because of potential increase in sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy; effect not studied
The 6 mg fixed dose is not for use in infants, children, and adolescents weighing <45 kg
Not indicated for peripheral blood progenitor cell (PBRC) mobilization for hematopoietic stem cell transplantation
Pegfilgrastim may potentially act as growth factor for any tumor type, including myeloid malignancies and myelodysplasia
Associated with rare cases of splenic rupture; evaluate if patient experiences left upper abdominal &/or shoulder tip pain
May precipitate sickle cell crises in patients with sickle cell anemia
The body Injector uses acrylic adhesive; for patients who have reactions to acrylic adhesives, use of this product may result in a significant reaction
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Recombinant PEG-conjugated human G-CSF; acts on hematopoietic cells to stimulate production, maturation & activation of neutrophilsl; increases migration and cytotoxicity of neutrophils.
Half-Life: 15-80 hr (adults); 20-30 hr (children)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs